Nuclear Medicine Therapy Side Effects and Complications /

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Giovanella, Luca (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2019.
• Έκδοση: 1st ed. 2019.
• Θέματα: Nuclear medicine.; Oncology .; Endocrinology .; Nursing-Study and teaching.; Nuclear Medicine.; Oncology.; Endocrinology.; Nursing Education.

 This book considers how Nuclear Medicine treatments have been further developed in the past several years and are now widely applied in clinical practice, especially in oncological patients, in addition to radioiodine therapy for various thyroid diseases. These treatments are very effective when properly indicated, but side effects and complications specifically related to the radioactive drugs and other potential clinical problems should also be considered, since other treatments, e.g. chemotherapy or radiotherapy, are frequently administered before, simultaneously with and/or after radionuclide therapies. Consequently, cumulative toxicities and treatment interactions must be considered, and physicians prescribing treatments should be capable of preventing (when possible) and properly diagnosing and treating such side effects and complications. Accordingly, expertise in radionuclide therapy and extensive clinical expertise are required to appropriately manage critical cases. This book provides essential information on the physiopathology and radiopharmacy of radionuclide treatments and addresses potential side effects and complications by providing a rapid consultation guide for clinicians: synopses, diagnostic flow-charts and treatment schedules for a range of nuclear medicine treatments. 

 Preface -- Acknowledgement.-Nuclear medicine theranostics: between atoms and patients -- Radioiodine therapy of benign thyroid diseases -- Radioiodine therapy of thyroid cancers -- Peptide radio-receptor therapy (pprt) of neuroendocrine tumors -- [I-131]-MIBG therapy of malignant pheochromocytomas and neuroblastoma -- Radiometabolic therapy of bone metastases -- Selective internal radiotherapy (sirt) of primary hepatic carcinoma and liver metastases -- Radioimmunotherapy of lymphomas.